A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies

Phillips, Jonathan A.; Grandhi, Taraka Sai Pavan; Davis, Myrtle; Gautier, Jean‐Charles; Hariparsad, Niresh; Keller, Douglas A.; Sura, Radhakrishna; Vleet, Terry R. Van

doi:10.1039/c9lc00925f

Cited by 32 publications

(36 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the IQ Consortium (see Related links), a non-profit organization consisting of pharmaceutical and biotechnology company representatives, partnered with US government funding agencies in 2016 to add enduser stakeholder perspectives to the field. The IQ Consortium recently published a series of manuscripts on the characterization and use of OoC sytems in safety and toxicity profiling applications 56,153 and for modeling skin 154 , lung 155 , the GI tract 156 , kidney 157 and liver 158 . with the International Space Station National Laboratory (ISS-NL), is using microgravity as a tool to investigate Earth-based disease pathologies such as formation of kidney stones that would otherwise be difficult or take too long to model on Earth.…”

Section: Co-operation and Development (Oecd) Guidance Document On The Validation And Internationalmentioning

confidence: 99%

Organs-on-chips: into the next decade

Low

Mummery

Berridge

et al. 2020

Nat Rev Drug Discov

603

484

View full text Add to dashboard Cite

Organs-on-chips (OoCs), also known as microphysiological systems or "tissue chips" (the terms are synonymous), have garnered substantial interest in recent years owing to their potential to be informative at multiple stages of the drug discovery and development process. These innovative devices could provide insights into normal human organ function and disease pathophysiology, as well as more accurately predict the safety and efficacy of investigational drugs in humans. Therefore, they are likely to become useful additions to traditional preclinical cell culture methods and in vivo animal studies in the near term, and in some cases, replacements for them in the longer term. In the last decade, the OoC field has seen dramatic advances in the sophistication of biology and engineering, in the demonstration of physiological relevance, and in the range of applications. These advances have also revealed new challenges and opportunities, and expertise from multiple biomedical and engineering fields will be needed to fully realize the promise of OoCs for fundamental and translational applications. This Review provides a snapshot of this fast-evolving technology, discusses current applications and caveats for their implementation, and offers suggestions for directions in the next decade.

show abstract

Section: Co-operation and Development (Oecd) Guidance Document On The Validation And Internationalmentioning

confidence: 99%

Organs-on-chips: into the next decade

Low

Mummery

Berridge

et al. 2020

Nat Rev Drug Discov

603

484

View full text Add to dashboard Cite

show abstract

“…12 A useful prioritization of MPS applications can be found in Table 1 of the review by Watson, Hunziker, and Wikswo, 2017. 10 Currently, there are MPS of nearly every major human organ 20 including liver, 16,41 vasculature, 42,43 blood-brain barrier (BBB), [44][45][46] skeletal [47][48][49] and cardiac muscle, [50][51][52][53][54][55][56][57] kidney, [58][59][60][61] female reproductive tissues (uterus, cervix, fallopian tubes), 62 testes, 63 brain, 37,64 skin, [65][66][67] gut, 40 bone, 68 and eye. 69,70 Specific MPS organ systems have also been linked to form multi-organ systems to more accurately depict systemic responses to a variety of drugs and therapeutics.…”

Section: Impact Statementmentioning

confidence: 99%

Microphysiological systems: What it takes for community adoption

Hargrove-Grimes

Low

Tagle

2021

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Microphysiological systems (MPS) are promising in vitro tools which could substantially improve the drug development process, particularly for underserved patient populations such as those with rare diseases, neural disorders, and diseases impacting pediatric populations. Currently, one of the major goals of the National Institutes of Health MPS program, led by the National Center for Advancing Translational Sciences (NCATS), is to demonstrate the utility of this emerging technology and help support the path to community adoption. However, community adoption of MPS technology has been hindered by a variety of factors including biological and technological challenges in device creation, issues with validation and standardization of MPS technology, and potential complications related to commercialization. In this brief Minireview, we offer an NCATS perspective on what current barriers exist to MPS adoption and provide an outlook on the future path to adoption of these in vitro tools.

show abstract

“…This activity has now been taken over as EUROoCS 3 . In the United States, the National Center for Advancing Translational Sciences (NCATS) 4 initially took the lead (Low and Tagle, 2017;Tagle, 2019) (Ainslie et al, 2019;Baudy et al, 2019;Fabre et al, 2019;Fowler et al, 2019;Hardwick et al, 2019;Philips et al, 2019 (Bircsak et al, 2021), can be seeded in the flow path, and Mimetas provides its applications on their website 9 . The culture platform is quite simple, as the medium perfusion system in the flow channel is gravity-induced, generated by continuous tilting of the plate with a seesaw shaker.…”

Section: Microphysiological Systemsmentioning

confidence: 99%

Research and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project

Ishida

2021

Front. Toxicol.

View full text Add to dashboard Cite

Microphysiological systems (MPS) have been actively developed as a new technology for in vitro toxicity testing platforms in recent years. MPS are culture techniques for the reconstruction of the specific functions of human organs or tissues in a limited space to create miniaturized human test systems. MPS have great promise as next-generation in vitro toxicity assessment systems. Here, I will review the current status of MPS and discuss the requirements that must be met in order for MPS to be implemented in the field of drug discovery, presenting the example of an in vitro cell assay system for drug-induced liver injury, which is the research subject in our laboratory. Projects aimed at the development of MPS were implemented early in Europe and the United States, and the AMED-MPS project was launched in Japan in 2017. The AMED-MPS project involves industry, government, and academia. Researchers in the field of drug discovery in the pharmaceutical industry also participate in the project. Based on the discussions made in the project, I will introduce the requirements that need to be met by liver-MPS as in vitro toxicity test platforms.

show abstract

A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies

Abstract: The human kidney contains approximately one million nephrons.

Cited by 32 publications

References 86 publications

Organs-on-chips: into the next decade

Organs-on-chips: into the next decade

Microphysiological systems: What it takes for community adoption

Research and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project

Contact Info

Product

Resources

About